William Alexander Vandergrift
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
William Alexander Vandergrift has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Aaron Miller
College of Osteopathic Medicine, New York Institute of Technology, Glen Head, New York
1 shared publication- Adam Seth Greenblatt
Neurology Department, Washington University in St. Louis, St Louis, MO
1 shared publication - Alicia Zukas
Department of Neurosurgery, Medical University of South Carolina, Charleston, SC 29425, USA
1 shared publication - Angela Alexander-Bryant
Department of Bioengineering, Clemson University, Clemson, SC 29634, USA
1 shared publication - Arabinda Das
Department of Neurosurgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA
1 shared publication Arie Perry
Department of Pathology, University of California, San Francisco, San Francisco, California, USA
1 shared publication
Latest Publications
- Open Access
Immune Resistance in Glioblastoma: Understanding the Barriers to ICI and CAR-T Cell Therapy
Background: Glioblastoma (GBM) is the most common primary malignant brain tumor, with fewer than 5% of patients surviving five years after diagnosis. The introduction of immune checkpoint inhibitors (ICIs), followed by chimeric antigen receptor (CAR) T-cell therapy, marked major advancements in oncology. Despite demonstrating efficacy in other blood and solid cancers, these therapies have yielded limited success in clinical trials for both newly diagnosed and recurrent GBM. A deeper understanding of GBM’s resistance to immunotherapy is essential for enhancing treatment responses and translating results seen in other cancer models. Objectives: In this review, we examine clinical trial outcomes involving ICIs and CAR-T for GBM patients and explore the evasive mechanisms of GBM and the tumor microenvironment. Findings and Discussion: Multiple clinical trials investigating ICIs in GBM have shown poor outcomes, with no significant improvement in progression-free survival (PFS) or overall survival (OS). Results from smaller case studies with CAR-T therapy have warranted further investigation. However, no large-scale trials or robust studies have yet established these immunotherapeutic approaches as definitive treatment strategies. Future research should shift focus from addressing the scarcity of functional T cells to exploiting the abundant myeloid-derived cells within the tumor microenvironment. Conclusions: Translating these therapies into effective treatments for glioblastoma in humans remains a significant challenge. The highly immunosuppressive nature of GBM and its tumor microenvironment continue to hinder the success of these innovative immunotherapeutic approaches. Targeting the myeloid-derived compartment may lead to more robust and sustained immune responses.
Open AccessImmune Resistance in Glioblastoma: Understanding the Barriers to ICI and CAR-T Cell Therapy
Background: Glioblastoma (GBM) is the most common primary malignant brain tumor, with fewer than 5% of patients surviving five years after diagnosis. The introduction of immune checkpoint inhibitors (ICIs), followed by chimeric antigen receptor (CAR) T-cell therapy, marked major advancements in oncology. Despite demonstrating efficacy in other blood and solid cancers, these therapies have yielded limited success in clinical trials for both newly diagnosed and recurrent GBM. A deeper understanding of GBM’s resistance to immunotherapy is essential for enhancing treatment responses and translating results seen in other cancer models. Objectives: In this review, we examine clinical trial outcomes involving ICIs and CAR-T for GBM patients and explore the evasive mechanisms of GBM and the tumor microenvironment. Findings and Discussion: Multiple clinical trials investigating ICIs in GBM have shown poor outcomes, with no significant improvement in progression-free survival (PFS) or overall survival (OS). Results from smaller case studies with CAR-T therapy have warranted further investigation. However, no large-scale trials or robust studies have yet established these immunotherapeutic approaches as definitive treatment strategies. Future research should shift focus from addressing the scarcity of functional T cells to exploiting the abundant myeloid-derived cells within the tumor microenvironment. Conclusions: Translating these therapies into effective treatments for glioblastoma in humans remains a significant challenge. The highly immunosuppressive nature of GBM and its tumor microenvironment continue to hinder the success of these innovative immunotherapeutic approaches. Targeting the myeloid-derived compartment may lead to more robust and sustained immune responses.
- Open Access
- 29 May 2023
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 5 (22)
Vasospasm secondary to responsive neurostimulator placement: a previously unreported complication. Illustrative case
BACKGROUND: The Responsive Neurostimulation (RNS) system is an implantable device for patients with drug-resistant epilepsy who are not candidates for resection of a seizure focus. As a relatively new therapeutic, the full spectrum of adverse effects has yet to be determined. A literature review revealed no previous reports of cerebral vasospasm following RNS implantation. OBSERVATIONS: A 35-year-old man developed severe angiographic and clinical vasospasm following bilateral mesial temporal lobe RNS implantation. He initially presented with concerns for status epilepticus 8 days after implantation. On hospital day 3, a decline in his clinical examination prompted imaging studies that revealed a left middle cerebral artery (MCA) stroke with angiographic evidence of severe vasospasm of the left internal carotid artery (ICA), MCA, anterior cerebral artery (ACA), and right ICA and ACA. Despite improvements in angiographic vasospasm after appropriate treatment, a thrombus developed in the posterior M2 branch, requiring mechanical thrombectomy. Ultimately, the patient was stabilized and discharged to a rehabilitation facility with residual cognitive and motor deficits. LESSONS: Cerebral vasospasm as a cause of ischemic stroke after uneventful RNS implantation is exceedingly rare, yet demands particular attention given the potential for severe consequences and the growing number of patients receiving RNS devices.
- 29 May 2023
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 5 (22)
Open AccessVasospasm secondary to responsive neurostimulator placement: a previously unreported complication. Illustrative case
BACKGROUND: The Responsive Neurostimulation (RNS) system is an implantable device for patients with drug-resistant epilepsy who are not candidates for resection of a seizure focus. As a relatively new therapeutic, the full spectrum of adverse effects has yet to be determined. A literature review revealed no previous reports of cerebral vasospasm following RNS implantation. OBSERVATIONS: A 35-year-old man developed severe angiographic and clinical vasospasm following bilateral mesial temporal lobe RNS implantation. He initially presented with concerns for status epilepticus 8 days after implantation. On hospital day 3, a decline in his clinical examination prompted imaging studies that revealed a left middle cerebral artery (MCA) stroke with angiographic evidence of severe vasospasm of the left internal carotid artery (ICA), MCA, anterior cerebral artery (ACA), and right ICA and ACA. Despite improvements in angiographic vasospasm after appropriate treatment, a thrombus developed in the posterior M2 branch, requiring mechanical thrombectomy. Ultimately, the patient was stabilized and discharged to a rehabilitation facility with residual cognitive and motor deficits. LESSONS: Cerebral vasospasm as a cause of ischemic stroke after uneventful RNS implantation is exceedingly rare, yet demands particular attention given the potential for severe consequences and the growing number of patients receiving RNS devices.
- 30 March 2021
- Published by Wiley in Journal of Neuroimaging
- Vol. 31 (3) , 551-559
Safety of MRI in the localization of implanted intracranial electrodes for refractory epilepsy
BACKGROUND AND PURPOSE This is an observational study to evaluate the safety of magnetic resonance imaging (MRI) to localize subdural grids and depth electrodes in patients with refractory epilepsy using a 1.5 Tesla MR scanner. METHODS We implemented an optimized MRI protocol providing adequate image quality for the assessment of subdural grids and depth electrodes, while minimizing the specific absorption rate (SAR). We reviewed all MRI studies performed in patients with subdural grids and depth electrodes between January 2010 and October 2018. Image quality was graded as acceptable or nonacceptable for the assessment of intracranial device positioning. We reviewed the medical record and any imaging obtained after intracranial implant removal for adverse event or complication occurring during and after the procedure. RESULTS Ninety‐nine patients with refractory epilepsy underwent MRI scans using a magnetization‐prepared rapid acquisition of gradient echo sequence and a transmit‐receive head coil with depth electrodes and subdural grids in place. Two patients underwent two separate depth electrode implantations for a total of 101 procedures and MRI scans. No clinical adverse events were reported during or immediately after imaging. Image quality was graded as acceptable for 97 MRI scans. Review of follow‐up CT and MRI studies after implant removal, available for 70 patients, did not demonstrate unexpected complications in 69 patients. CONCLUSION In our experience, a low SAR MRI protocol can be used to safely localize intracranial subdural grids and depth electrode in patients with refractory epilepsy.
- 30 March 2021
- Published by Wiley in Journal of Neuroimaging
- Vol. 31 (3) , 551-559
Safety of MRI in the localization of implanted intracranial electrodes for refractory epilepsy
BACKGROUND AND PURPOSE This is an observational study to evaluate the safety of magnetic resonance imaging (MRI) to localize subdural grids and depth electrodes in patients with refractory epilepsy using a 1.5 Tesla MR scanner. METHODS We implemented an optimized MRI protocol providing adequate image quality for the assessment of subdural grids and depth electrodes, while minimizing the specific absorption rate (SAR). We reviewed all MRI studies performed in patients with subdural grids and depth electrodes between January 2010 and October 2018. Image quality was graded as acceptable or nonacceptable for the assessment of intracranial device positioning. We reviewed the medical record and any imaging obtained after intracranial implant removal for adverse event or complication occurring during and after the procedure. RESULTS Ninety‐nine patients with refractory epilepsy underwent MRI scans using a magnetization‐prepared rapid acquisition of gradient echo sequence and a transmit‐receive head coil with depth electrodes and subdural grids in place. Two patients underwent two separate depth electrode implantations for a total of 101 procedures and MRI scans. No clinical adverse events were reported during or immediately after imaging. Image quality was graded as acceptable for 97 MRI scans. Review of follow‐up CT and MRI studies after implant removal, available for 70 patients, did not demonstrate unexpected complications in 69 patients. CONCLUSION In our experience, a low SAR MRI protocol can be used to safely localize intracranial subdural grids and depth electrode in patients with refractory epilepsy.
- 5 February 2021
- Published by Elsevier in Epilepsy Research
- Vol. 171, 106571
Patterns of seizure spread in temporal lobe epilepsy are associated with distinct white matter tracts
- 5 February 2021
- Published by Elsevier in Epilepsy Research
- Vol. 171, 106571
Patterns of seizure spread in temporal lobe epilepsy are associated with distinct white matter tracts
- 1 December 2016
- Published by Elsevier in World Neurosurgery
- Vol. 96, 403-409
Intracranial Angiomatoid Fibrous Histiocytoma: Case Report and Literature Review
- 1 December 2016
- Published by Elsevier in World Neurosurgery
- Vol. 96, 403-409
Intracranial Angiomatoid Fibrous Histiocytoma: Case Report and Literature Review